Table 3.

Psoriasis and cardiovascular diseases comorbidity strength of recommendation and level of evidence.

Recommendation	Strength of recommendation	Level of evidence
Risk assessment  Recommended for all patients with psoriasis	B	II-III
Screening  Early and more frequent screening for hypertension, diabetes, and  hyperlipidemia in patients who are candidates for systemic or phototherapy or  who have psoriasis involving >10% body surface area	B	II-III
Risk score models  Should be adapted by introducing a 1.5 multiplication factor for  patients with either >10% body surface area involvement or  those who are candidates for systemic or phototherapy	C	II-III
Risk management  Should be carried out according to national guidelines and performed by  either primary care physician or dermatologist.  Target blood pressure and lipid levels are based on risk as previously calculated  Antihypertensives and statins may be used as in general population	C	III